Research analysts at TD Cowen initiated coverage on shares of Centessa Pharmaceuticals (NASDAQ:CNTA – Get Free Report) in a report issued on Tuesday, Marketbeat Ratings reports. The firm set a “buy” ...

Fintel reports that on January 7, 2025, TD Cowen initiated coverage of Centessa Pharmaceuticals plc - Depositary Receipt () ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Senseonics Holdings (SENS – Research Report) ...

Centessa is rapidly advancing a potential best-in-class and first-in-class portfolio of orexin receptor 2 (OX2R) agonists with a robust series of clinical milestones anticipated this year,” said ...

We recently published an article entitled Why These 10 Stocks Jumped Yesterday. In this article, we are going to take a look ...

Centessa Pharmaceuticals, founded from the merger of 10 biotech companies, is based on an asset-centric model, primarily ...

Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report)’s share price dropped 3.2% on Tuesday . The stock traded as low ...

Current share price of US$16.75 suggests Centessa Pharmaceuticals is potentially 30% undervalued ...

波士顿 - 市值22.8亿美元的临床阶段制药公司Centessa Pharmaceuticals plc (NASDAQ:CNTA)宣布任命Stephen Kanes医学博士为新任首席医疗官。Kanes博士是一位在神经科学、临床精神病学和药物开发方面拥有30多年经验的神经精神病学专家。他加入Centessa之际，公司正在推进其催眠素受体2 (OX2R)激动剂组合的开发，预计今年将达成多个临床里程碑 ...

Centessa Pharmaceuticals has entered into a loan and security agreement with Oxford Finance LLC, securing up to $200 million in term loans to refinance existing debt and support its operations.

Check the time stamp on this data. Updated AI-Generated Signals for Centessa Pharmaceuticals Plc (CNTA) available here: CNTA.

周二，研究公司Cowen开始对Centessa Pharmaceuticals (NASDAQ:CNTA)股票进行覆盖，给予该公司买入评级。这一决定得到了Centessa药物候选ORX750潜力的支撑，该药物正在开发用于治疗过度日间嗜睡。